GenSight Biologics Reports Cash Status and Early Access Revenues

GenSight Biologics announced its financial position and revenue from its Early Access Program as of March 31, 2026. The biopharma company, focusing on gene therapies for retinal diseases, reported cash and equivalents of €3.2 million, up from €2.4 million at the end of 2025. This increase partly results from a €1.7 million fundraising effort in March 2026.

The company's operating cash burn largely supports the GS010 Early Access Programs and prepares for a Phase III study of LUMEVOQ® targeted at Leber Hereditary Optic Neuropathy. Initial revenues of €2.6 million from its French Early Access Program were recorded in March 2026. The GS010/LUMEVOQ® treatment price is set at €425,000 per injection, with additional treatments anticipated in April. The company projects that early access program revenues in 2026 will cover operating costs, excluding expenses related to its ongoing clinical trial.